Background: Intravenous iron is commonly utilised in pregnancy when treatment with oral is not tolerated or where rapid replenishment of iron stores is required.
Introduction
Iron deficiency is the leading cause of anaemia in pregnancy, 1 which in turn is associated with significant perinatal morbidity and mortality.
1,2 Therefore, improvements in haematological status in pregnancy through appropriate replenishment of depleted iron stores are considered important in supporting optimal perinatal outcomes. 3 Suggested approaches towards diagnosis and management of iron-deficiency anaemia in pregnancy can be found elsewhere. 4, 5 According to such algorithms, intravenous iron therapy plays an important role where oral iron therapy is either not tolerated or unsuitable, such as in the setting of imminent delivery where rapid restoration of iron status is required. 4, 5 While a number of different intravenous formulations of iron has been studied in pregnancy, 6 dosing strategies are often inconsistent, and there has been no examination of the optimal dosing weight to use when calculating body iron deficit and subsequent iron dose. This is of particular concern given the increasing prevalence of overweight and obesity in pregnancy, leading to confusion in what dosing weight to use.
Traditional dosing regimens have utilised the Ganzoni formula, 7 but this has been criticised for its difficulty of use, susceptibility to calculation errors, inconsistent use in clinical practice and underestimation of total iron replacement requirements. 8 More recently, a Simplified Dosing Method has been trialled alongside the use of a new formulation of intravenous iron, ferric carboxymaltose, 9 but how doses calculated using this method compare to alternative regimens remain unclear. Therefore, this study aimed to explore the relationship between the dose of intravenous iron administered and haematological outcomes and compare recommended doses according to different dose calculation methods.
Methods

Study cohort and data collection
We conducted a retrospective cohort study of all women receiving intravenous iron polymaltose for the management of iron deficiency anaemia between 1 January 2014 and 31 January 2016 at Flinders Medical Centre (FMC) in Adelaide, South Australia. FMC is a tertiarylevel teaching hospital caring for more than 3000 births each year. Pregnant women prescribed intravenous iron polymaltose were identified by matching the electronic pharmacy dispensing records to the electronic perinatal hospital records. We excluded women receiving IV iron who did not have anaemia. Paper-based case notes were then examined to verify that the infusion was administered and that the women were indeed pregnant at the time of infusion. Women were identified as being anaemic based on a haemoglobin (Hb) value less than 110 g/L in the first trimester and 105 g/L during the second or first trimester. 5 Iron deficiency was defined as serum ferritin less than 30 mcg/L or serum transferrin ≤16%. 10 A standardised electronic data collection tool was used to collect patient demographics, obstetric and medical history, infusion-related data, haematological data, iron studies and perinatal outcomes from a combination of electronic and paper-based medical records.
Investigation of dose-response relationship
The local clinical practice guideline for intravenous iron is to calculate total iron deficit according to the Ganzoni equation Iron dose = weight × target Hb -current Hb ð Þ × 0:24 + 500 mg
The guideline recommends a target Hb of 150 g/L, but it does not specify which weight must be used when calculating the dose (i.e. whether to use pre-pregnancy or current weight). In order to investigate dose-response relationships, the prescribed dose was divided by different patient weights, including booking weight (which was estimated to be a close approximation of prepregnancy weight), ideal bodyweight and adjusted bodyweight. Ideal bodyweight was calculated using the following equation: 45.5 kg + 0.9 kg/cm for each cm over 152 cm. 11 Adjusted bodyweight was calculated using the following equation: IBW + [0.4 × (TBW -IBW)]. 12 Response to IV iron was evaluated by exploring changes in Hb from immediately prior to IV iron infusion to 2-4 weeks post-treatment and also at delivery. Women were classified as having treatment success if they had an Hb increase of 20 g/L prior to delivery. The presence of anaemia at delivery (Hb < 105 g/L) was also examined.
Comparison of dose calculation methods
Weight-based estimate of blood volume was determined Added to this is the 500 mg of elemental iron required to replenish body iron stores. 7 The calculated iron deficit according to the weightbased estimate of blood volume was regarded as the true iron deficit and then compared to the dose of iron calculated according to the Ganzoni formula or Simplified Dosing Method (Table 1) . For the purposes of comparison, we took a woman of average height (162 cm) with varying degrees of anaemia (from 100 g/L to 70 g/L) and calculated iron deficits according to pre-pregnancy weight ranging from 60 to 100 kg. Calculations using the Ganzoni formula were undertaken using three different dosing weights, including total bodyweight, adjusted bodyweight and ideal bodyweight. Calculations using the Simplified Method solely rely on a weight less than, greater than or equal to 70 kg.
Statistical analysis
Adjusted differences in continuous (i.e. Hb Change) or categorical (i.e. Hb Success) outcomes according to increasing maternal intravenous iron dose (i.e. mg/kg according to ideal bodyweight, adjusted bodyweight or total bodyweight) were compared using linear regression analysis and a generalised linear model (Poisson distribution) with robust variance estimates (and resulting relative risks (RR) and 95% confidence intervals) respectively. Analyses were adjusted for possible confounders, including gestation at the time of infusion, Hb status at the time of infusion and maternal body mass index (BMI). Statistical significance was defined as a two-sided P-value of <0.05. All data analysis was undertaken using Stata SE 14 (Stata, College Station, TX, USA). 
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Results
A total of 122 pregnancies was identified where women had confirmed iron deficiency anaemia and received a single infusion of intravenous iron polymaltose. The number of women who had a repeat Hb at either 2-4 weeks post-infusion or prior to delivery was 65 and 110 respectively. There were only nine women who did not have a repeat Hb at either time point, with characteristics of the study cohort outlined in Table 2 .
The majority of women were of Caucasian ethnicity (65%), multi-parous (67%) and had trialled oral iron prior to receiving an IV dose (79%), while a small number had documented intolerance to oral iron (20%). Approximately half were overweight or obese (54%), with a mean age of 28.5 (AE5.5) years. On average, women were 33.2 (AE3.6) weeks into gestation, with a mean Hb of 95 (AE7) g/L at the time of infusion. The median dose of intravenous iron was 1400 mg and ranged from 800 mg to 2000 mg. Dose-response relationships were evident between change in Hb from treatment until delivery and intravenous iron dose according to adjusted bodyweight (adjusted beta coefficient 0.70 (0.24-1.15)) and prepregnancy total bodyweight (adjusted beta coefficient 
116 (13) 118 ( (Table 3 ). Significant variability was evident in the calculated iron deficit and required doses according to different calculation methods (Fig. 1) . In all examples, dosing using the Ganzoni formula and dosing according to adjusted bodyweight most closely estimated the iron deficit according to the weight-based total blood volume. As pre-pregnancy bodyweight increased (corresponding to overweight or obesity), the use of the Ganzoni formula and total bodyweight or ideal bodyweight progressively led to over-or under-dosing of iron, respectively, by as much as 200-500 mg of iron, with greater discrepancy in dosing with greater anaemia severity. Similarly, calculating iron doses according to the Simplified Dosing Regimen often led to over-or under-dosing of iron, depending on which dosing weight was used and the severity of anaemia. When pre-pregnancy ideal bodyweight and total bodyweight were similar (i.e. when BMI < 25), the dose recommended by the Simplified Dosing Method provided a close approximation to the iron deficit (AE250 mg). However, accuracy of dosing appeared to change significantly as total bodyweight increased. In the instance of mild anaemia (Hb above 100 g/L), administering 1000 mg of iron according to ideal bodyweight (i.e. <70 kg) using the Simplified Dosing Method resulted in underestimation of the iron deficit by 250-400 mg in the setting of overweight/obesity. In contrast, where Hb is between 80 g/L and 99 g/L, administering 1500 mg of iron according to ideal bodyweight using the Simplified Dosing Method provided a dose within 200 mg of the estimated iron deficit. If given 2000 mg of iron according to total bodyweight (i.e. ≥70 kg) using the Simplified Dosing Method, the administered dose would be 200-600 mg in excess of the calculated iron deficit, representing potential overdosing. In the instance of severe anaemia (Hb around 70 g/L), however, administering 1500 mg of iron according to ideal bodyweight using the Simplified Dosing Method resulted in underestimation of the iron deficit by 200-400 mg in the setting of overweight/ obesity.
Discussion
The discovery of a dose-response relationship between increasing doses of intravenous iron according to total or adjusted pre-pregnancy bodyweight and improved haematological response is of great importance given the negative outcomes associated with anaemia in pregnancy. This, together with physiological data on estimated blood volumes, provides evidence that optimal treatment outcomes in pregnant women requiring intravenous iron may be reached by dosing according to adjusted bodyweight, rather than ideal bodyweight. Furthermore, if the Simplified Dosing Method is used to calculate iron doses (as is most commonly performed with ferric carboxymaltose), significant caution must be applied when considering the appropriate dosing weight for women who are overweight or obese as the dose administered can over-or underestimate total body iron deficit by as much as 500 mg.
We are not aware of previous studies investigating the dose-response relationship for intravenous iron administration in pregnancy or any studies evaluating optimal dosing of iron in pregnant women who are overweight or obese. This is of significant importance given the increasing proportion of women entering pregnancy overweight or obese. Within Australia, as well as internationally, a number of clinical guidelines recommend dosing intravenous iron according to ideal bodyweight if the individual is overweight or obese.
14 This approach, however, does not appear to be informed by any direct evidence and appears in contrast to information provided from physiological and pharmacokinetic data. In general, medication dosing in overweight and obesity represents a common prescribing challenge as it is associated with alterations in drug pharmacokinetics. 15 These alterations can lead to requirements for changes in medication dosing regimens, but such alterations are medication-specific, and their resultant impact on clinical outcomes are variable and often not well studied. Given that body composition varies as a function of total bodyweight, optimising dosing in this population requires the identification of size descriptors, such as adjusted bodyweight, that share a quantitative relationship with changes in pharmacokinetics and associated pharmacological activity. When it comes to intravenous iron, it has been previously demonstrated that pregnant women who are overweight or obese have a greater total blood volume, 16 which in turn would require a greater amount of iron to increase haemoglobin concentration relative to an individual of ideal bodyweight and a lower total blood volume.
Recently, studies have suggested that the administration of ferric carboxymaltose according to the Simplified Dosing Method produces superior haematological outcomes than the administration of iron sucrose according to the Ganzoni formula. 8, 9 However, a key factor overlooked in these studies was that a normalised dosing weight was utilised for any individuals with a BMI > 25 kg/m 2 . That is, doses were capped at the weight corresponding to a BMI of 25 kg/m 2 for any individual with a BMI > 25 kg/m 2 . Our weight-based blood volume calculations clearly demonstrate an increase in iron requirements with increasing bodyweight; therefore, it is not surprising that these previous studies found that capping the iron dose at a BMI of 25 kg/m 2 resulted in underdosing. Regardless of this key factor, the findings have been routinely interpreted as the superiority of the Simplified Dosing Method over the traditional Ganzoni formula, and its use is now widespread in clinical practice as the use of ferric carboxymaltose increases. Our dosing examples, however, clearly demonstrate the need for 
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Internal Medicine Journal 47 (2017) 747-754caution when using the Simplified Dosing Method to calculate iron doses as confusion around what dosing weight to use, which is the challenge in treating women who are overweight or obese, can lead to significant over-or underestimation of total body iron deficit. Therefore, the dosing of intravenous iron in pregnancy appears to reflect a more nuanced maternal and foetal risk-versus-benefit consideration. Based on current evidence, the potential under-dosing of intravenous iron and resultant sub-therapeutic treatment response would appear a more significant concern in pregnancy, especially given the increasing prevalence of overweight and obesity. That said, it must be noted that the potential harms of over-dosing on iron are not well studied. This suggests that dosing of intravenous iron in pregnancy lends itself to a more individualised approach with consideration of factors, such as overweight or obesity, prepregnancy as opposed to current bodyweight, time to delivery and likelihood of further bleeding, all influencing the ideal dose to be administered. A key factor often overlooked when using the Simplified Dosing Method is that it includes 500 mg to replace body iron stores. The question is whether this is required in late pregnancy; as long as haemoglobin is increased to an acceptable level, iron stores will increase by as much as 200-300 mg as a result of maternal erythrocyte recycling following delivery. 17 Of course, this recycling will not occur among women who experience significant blood loss during or following delivery and represents the key challenge facing clinicians when determining the optimal dose to prescribe.
Both pregnancy and obesity are associated with dysregulation of iron metabolism. Pregnancy is associated with a reduction in the iron-regulatory hormone hepcidin, which is involved in regulating intestinal iron absorption, plasma iron concentrations and tissue iron distribution. 18 Hepcidin levels decrease across pregnancy, with the lowest levels apparent in the third trimester, and serve to alter iron homeostasis in an attempt to match increasing iron demands to meet the expansion in maternal haemoglobin mass and to satisfy the requirements for foetal growth. 4 Similarly, obesity is associated with an increased risk of iron deficiency anaemia. 19 While obesity is also associated with an increase in total blood volume and resultant dilutional hypoferraemia, in contrast to pregnancy, it is associated with an increase in circulating hepcidin. 19 These higher levels of hepcidin are associated with a reduction in intestinal iron absorption (leading to inadequate absorption of dietary iron and an increased risk of treatment failure with oral iron) and resultant decrease in iron availability, 19 in addition to impaired placental iron transfer and subsequent reduced neonatal iron status. 20 While further research is required to investigate the relationship between obesity, iron status and response to iron treatments in pregnancy, current evidence points towards the important role of optimising intravenous iron dosing in these women to enhance perinatal health outcomes.
A limitation of this study is the reliance on information obtainable from electronic or paper-based records and on tests ordered by clinicians as part of routine clinical care, with complete data on haematological outcomes not available for all women at every time point studied. We did not have data available on oral iron use following receipt of IV iron, which may have influenced treatment response. Furthermore, any suggestion for increasing intravenous iron dosing must be balanced against the unknown harms of administering too much IV iron, with any potential negative consequences on the foetus remaining undetermined. Supporting such potential concerns are data associating adverse pregnancy outcomes with high Hb concentrations.
21,22
Conclusion
We observed a dose-response relationship between increasing doses of intravenous iron according to total or adjusted pre-pregnancy bodyweight and improved haematological response. In light of these findings, further studies investigating both maternal and neonatal outcomes according to different dosing strategies are urgently needed to optimise intravenous iron dosing. In the meantime, clinicians should be cautious about utilising Simplified Dosing Methods and lean bodyweight for calculating intravenous iron doses as these can lead to significant over-or under-dosing. Ideally, adjusted bodyweight should be utilised to calculate the most accurate iron deficit and then an individualised approach taken to take into account the clinical circumstances of the individual, including future bleeding risk and requirement for replacement of iron stores prior to delivery, before determining the most appropriate dose.
